NEWS & MEDIA
Press Releases
27/8/2026
Myopharm Reports Preliminary Findings from TriGlytza® Type 1 Diabetes Pilot Study
31/7/2026
Myopharm’s Phase 2a Resilience-2a Clinical Trial Cleared to Advance Following Australian Ethics and FDA Review
29/6/2026
29/6/2026
Myopharm Advances Site Selection for RESILIENCE-2a Trial in Australia
13/6/2026
Forbes: The Aussie biotech betting on life after Ozempic
29/4/2026
Prescriber Survey Highlights Commercial Potential of TriGlytza®
22/4/2026
Management and Scientific Appointments
9/3/2026
TriGlytza® Preclinical Data Abstract
25/2/2026
Filing of Provisional Patent
20/2/2026
6-year Exclusive Distribution Agreement Signed with Pharmaco
4/2/2026
Myopharm CRO Appointment
24/12/2025
Myopharm December Update
6/8/2025
TriGlytza® achieves significant reduction in HbA1c% in Pre-Clinical Type 2 Diabetes
25/7/2025
Myopharm Appoints Dr Trevor Lockett to the Board of Directors
16/7/2025
Myopharm Clinical & Preclinical Trials and Partnership Update
20/6/2025
3-Year Partnership Signed with Diabetes Australia